IDYA
Price
$26.22
Change
+$0.29 (+1.12%)
Updated
Sep 24, 12:07 PM (EDT)
Capitalization
2.27B
48 days until earnings call
PDSB
Price
$1.06
Change
+$0.01 (+0.95%)
Updated
Sep 24, 12:21 PM (EDT)
Capitalization
49.38M
49 days until earnings call
Interact to see
Advertisement

IDYA vs PDSB

Header iconIDYA vs PDSB Comparison
Open Charts IDYA vs PDSBBanner chart's image
IDEAYA Biosciences
Price$26.22
Change+$0.29 (+1.12%)
Volume$2.96K
Capitalization2.27B
PDS Biotechnology
Price$1.06
Change+$0.01 (+0.95%)
Volume$150
Capitalization49.38M
IDYA vs PDSB Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. PDSB commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and PDSB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (IDYA: $25.93 vs. PDSB: $1.05)
Brand notoriety: IDYA and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 82% vs. PDSB: 79%
Market capitalization -- IDYA: $2.27B vs. PDSB: $49.38M
IDYA [@Biotechnology] is valued at $2.27B. PDSB’s [@Biotechnology] market capitalization is $49.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while PDSB’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 3 bearish.
  • PDSB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than PDSB.

Price Growth

IDYA (@Biotechnology) experienced а +4.89% price change this week, while PDSB (@Biotechnology) price change was -12.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.10%, and the average quarterly price growth was +53.89%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

PDSB is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.27B) has a higher market cap than PDSB($49.4M). IDYA YTD gains are higher at: 0.895 vs. PDSB (-35.583). PDSB has higher annual earnings (EBITDA): -32.36M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. PDSB (31.9M). PDSB has less debt than IDYA: PDSB (18.5M) vs IDYA (26.6M). IDYA has higher revenues than PDSB: IDYA (7M) vs PDSB (0).
IDYAPDSBIDYA / PDSB
Capitalization2.27B49.4M4,601%
EBITDA-380.2M-32.36M1,175%
Gain YTD0.895-35.583-3%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash670M31.9M2,100%
Total Debt26.6M18.5M144%
FUNDAMENTALS RATINGS
IDYA vs PDSB: Fundamental Ratings
IDYA
PDSB
OUTLOOK RATING
1..100
7917
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4791
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (30) in the Pharmaceuticals Major industry is in the same range as IDYA (61) in the null industry. This means that PDSB’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (69) in the null industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to PDSB’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as PDSB (99) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to PDSB’s over the last 12 months.

IDYA's Price Growth Rating (47) in the null industry is somewhat better than the same rating for PDSB (91) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than PDSB’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAPDSB
RSI
ODDS (%)
Bearish Trend 1 day ago
72%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 22 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 13 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGRCX43.410.06
+0.14%
MFS International Growth C
FGDCX45.38N/A
N/A
Fidelity Advisor Gold C
AUUYX25.27-0.13
-0.51%
AB Select US Equity Advisor
BIRCX22.99-0.14
-0.61%
BlackRock Sustainable Adg Lg Cp Cr C
RMOYX26.56-0.28
-1.04%
Victory RS Mid Cap Growth Y

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.04%
IMNM - IDYA
60%
Loosely correlated
+8.09%
SYRE - IDYA
59%
Loosely correlated
+4.77%
NRIX - IDYA
58%
Loosely correlated
-2.25%
CGON - IDYA
57%
Loosely correlated
-0.92%
CRNX - IDYA
57%
Loosely correlated
+6.35%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with DYN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-2.78%
DYN - PDSB
44%
Loosely correlated
-1.86%
VRDN - PDSB
42%
Loosely correlated
+0.05%
IDYA - PDSB
42%
Loosely correlated
+0.04%
RGNX - PDSB
42%
Loosely correlated
-1.43%
ARCT - PDSB
42%
Loosely correlated
-3.66%
More